Lessons From The Pfizer Off-Label Settlement: Compliance Programs Not Enough To Demonstrate Integrity, DOJ Says
A lesson of Pfizer's $2.3 billion corporate integrity settlement with the Department of Justice is that good integrity policies are meaningless without employee adherence, according to government attorneys
You may also be interested in...
The era of big pharma off-label promotion cases may be coming to a close, but federal prosecutors are eyeing other industry practices for enforcement, including unsupported promotional claims of economic superiority and superior efficacy, and manipulation of the average sales price system.
The government may be hoping the third time's the charm as it enters into a new corporate integrity agreement with Pfizer
Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior
Pfizer's $2.3 billion settlement with the U.S. Department of Justice is unprecedented in size and scope, resolving allegations of off-label marketing of four drugs and kickbacks to health care providers involving nine other drugs. Moreover, the deal includes the largest criminal fine ever imposed by the U.S. government in any matter